Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Chalcis – page 10

159 clinical trials in Chalcis, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Chalcis at a glance
159
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

159 trials in Chalcis

Open in trial search

Prostate cancer

Not recruiting

Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Amgen Inc.

A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

A study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Study of oral and injectable NNC0487-0111 (Amycretin) to find the best dose for blood sugar control in adults with type 2 diabetes taking metformin with or without SGLT2 inhibitor

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Metformin Embonate
  • Sponsor:Novo Nordisk A/S

Hypertension

Not recruiting

Study of orforglipron in people with high blood pressure who are overweight or have obesity

Investigational
Countries:GreeceGreece
  • Participants:18–64 years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

Type 2 diabetes mellitus+1

Not recruiting

Study on the Effectiveness of Survodutide for Weight Loss in Patients with Type 2 Diabetes and Obesity

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Survodutide
  • Sponsor:Boehringer Ingelheim Espana S.A.

Atrial fibrillation+1

Not recruiting

Study on Flecainide and Amiodarone for Treating Atrial Fibrillation in Patients with Coronary Artery Disease and Ejection Fraction Over 35%

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Flecainide Acetate
  • Sponsor:Win Medica Pharmaceutical S.A.

Study of PF-06821497 and Enzalutamide for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Study of PF-06821497 with Enzalutamide for Men with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Pfizer Inc.

Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years
  • Substances:Tolebrutinib
  • Sponsor:Genzyme Corp.

Study on the Effects and Safety of Efgartigimod PH20 SC for Adults with Active Idiopathic Inflammatory Myopathy

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Other cities in Greece

The busiest research cities in the country

All 48 cities in Greece

Clinical research in Chalcis

What the registry says about research in the country

01 Cardiovascular Diseases

Clinical trial activity in Chalkida is focused entirely on cardiovascular diseases, with studies centered on different forms of heart failure. The research is mainly aimed at evaluating new treatment approaches that may help reduce serious heart-related events and improve symptom control.

  • Heart failure with reduced ejection fraction
  • HFpEF and HFmrEF linked to obesity
  • Heart failure with systemic inflammation
  • Testing whether new therapies can improve outcomes beyond standard care

These trials are exploring both treatment effectiveness and the potential to lower risks such as cardiovascular death, hospitalisation, and urgent care visits.

02 Heart Failure Research

Current studies in this area are examining whether targeted therapies can better manage symptomatic heart failure in patients whose condition remains difficult to control. The focus is on improving long-term outcomes for people with more advanced forms of the disease.

  • HFrEF with severely reduced ejection fraction
  • Comparing a new treatment with placebo
  • Assessing added benefit alongside guideline-directed medical therapy

This line of research aims to clarify whether new options can offer meaningful benefit in everyday clinical care.

03 Inflammation and Obesity in Heart Failure

Another important research theme links heart failure with systemic inflammation and obesity, reflecting growing interest in how these factors influence disease progression. The studies are designed to test whether newer therapies can address these overlapping risks more effectively.

  • HFpEF and HFmrEF with obesity
  • Heart failure with inflammation
  • Evaluating whether treatment can reduce major cardiovascular events
  • Supporting better control of complex, mixed-risk patient groups

Together, these trials reflect a focused effort in Greece to improve care for people living with challenging forms of heart failure.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.